'Study treatment' presentation slideshows

947 views • 63 slides

Study Procedures & Operational Issues

Study Procedures & Operational Issues. Start-up Meeting March 25, 2010 Kingston, ON. CERU Contacts. Role of Study Coordinator. Regulatory Screening & Randomization Pharmacy Communication Blood Sample Draws Data Collection Monitoring Study Intervention Administration

736 views • 61 slides

CDISC SDTM IG for Associated Persons 1.0 Overview

478 views • 43 slides

Progress Report, June 2006: CDRP Grant Programs

307 views • 20 slides

Background

315 views • 20 slides

Progress Report, June 2006: CDRP Grant Programs

212 views • 20 slides

HPS2-THRIVE: Treatment of HDL to Reduce the Incidence of Vascular Events

HPS2-THRIVE: Treatment of HDL to Reduce the Incidence of Vascular Events. Financial Disclosure : Designed , conducted and analysed by Oxford University independently of the grant source (Merck & Co). No honoraria or consultancy fees accepted. Jane Armitage on behalf of the

144 views • 14 slides

Enrollment and Outcomes

Enrollment and Outcomes. Fan Fan Hou, et al. N Engl J Med 2006;354:131-40. Baseline Characteristics of the Patients with Chronic Kidney Disease*. Fan Fan Hou, et al. N Engl J Med 2006;354:131-40.

198 views • 8 slides

557 patients included in the ITT efficacy analysis 555 assessed for EGFR expression

1861 patients screened 1688 with tumors suitable for EGFR expression assessment. 321 excluded 183 did not meet inclusion criteria 79 refused to participate 59 other reasons. 1442 patients with EGFR-expressing tumors. 4 EGFR status unknown. 1125 randomly assigned ITT population.

183 views • 1 slides